HEPION PHARMACEUTICALS INC (HEPA)
US4268973025 - Common Stock
We assign a fundamental rating of 2 out of 10 to HEPA. HEPA was compared to 198 industry peers in the Pharmaceuticals industry. HEPA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HEPA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year HEPA has reported negative net income.
HEPA had a negative operating cash flow in the past year.
In the past 5 years HEPA always reported negative net income.
HEPA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of HEPA (-270.41%) is worse than 92.82% of its industry peers.
Looking at the Return On Equity, with a value of -672.04%, HEPA is doing worse than 84.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -270.41% | ||
| ROE | -672.04% | ||
| ROIC | N/A |
ROA(3y)-125.76%
ROA(5y)-95.95%
ROE(3y)-266.01%
ROE(5y)-185.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for HEPA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, HEPA has more shares outstanding
The number of shares outstanding for HEPA has been increased compared to 5 years ago.
HEPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -24.47, we must say that HEPA is in the distress zone and has some risk of bankruptcy.
HEPA has a Altman-Z score of -24.47. This is amonst the worse of the industry: HEPA underperforms 86.15% of its industry peers.
HEPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -24.47 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 3.31 indicates that HEPA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.31, HEPA is in line with its industry, outperforming 51.28% of the companies in the same industry.
HEPA has a Quick Ratio of 3.31. This indicates that HEPA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.31, HEPA is in line with its industry, outperforming 55.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.31 |
3. Growth
3.1 Past
HEPA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.41%.
EPS 1Y (TTM)-4.41%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q6.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, HEPA will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.01% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.37%
EPS Next 2Y25.28%
EPS Next 3Y13.6%
EPS Next 5Y10.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
HEPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HEPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HEPA's earnings are expected to grow with 13.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.28%
EPS Next 3Y13.6%
5. Dividend
5.1 Amount
No dividends for HEPA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HEPION PHARMACEUTICALS INC
NASDAQ:HEPA (4/24/2024, 3:43:18 PM)
After market: 1.38 +0.06 (+4.55%)1.32
-0.17 (-11.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.73M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -270.41% | ||
| ROE | -672.04% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-4.41%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y5.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y